-
Eptifibatide
- indication:For treatment of myocardial infarction and acute coronary syndrome.
- pharmacologypharmacology:
- mechanism: Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. Inhibition of platelet aggregation occurs in a dose- and concentration-dependent manner.
- toxicity: Eptifibatide was not lethal to rats, rabbits, or monkeys when administered by continuous intravenous infusion for 90 minutes at a total dose of 45 mg/kg (about 2 to 5 times the recommended maximum daily human dose on a body surface area basis)
- absorprion:
- halflife: Approximately 2.5 hours
- roouteelimination:
- volumedistribution:
- clearance: * 55 mL/kg/h [patients with coronary artery disease]